Professor, Biochemistry and Molecular Genetics
- PhD, Molecular Cell Biology, University of Tokyo
- Postdoc, Cancer Biology, Harvard Medical School
Biochemistry, Cancer Biology, Epigenetics, Experimental Pathology, Genetics, Molecular Biology, Molecular Pharmacology
Cell signaling, stem cell biology, molecular and epigenetic mechanisms of blood and breast cancers
My laboratory focuses on understanding the molecular and epigenetic mechanisms involved in the regulation of normal hematopoiesis and hematologic malignancies. The ultimate goal of our research is to identify new therapeutic targets and develop novel therapeutic strategies for treatment of leukemia. JAK2, a member of the Janus family of non-receptor protein tyrosine kinases, is activated in response to a variety of cytokines. A somatic JAK2V617F mutation has been found in a majority of patients with myeloproliferative neoplasms (MPNs). One of the major interests in our lab is to study the role of the JAK/STAT signaling in the pathogenesis of MPNs. We are also investigating the interaction of epigenetic modulators with the JAK2 mutation in MPNs using state-of-the-art techniques and genetically engineered animal models.
Current research projects in my laboratory are focused in the following areas:
(1) Elucidation of the role of oncogenic JAK2 mutation in the pathogenesis of myeloproliferative neoplasms.
(2) Investigation of the role of tyrosine phosphatases (e.g, PTPN1, PTPN11) in myeloid neoplasms.
(3) Investigation of the role of RNA splicing factor mutations in myeloid neoplasms.
(4) Investigation of the effects of epigenetic modifier mutations in myeloid malignancies.
(5) Identification of new therapeutic targets and therapies for triple negative breast cancer.